Browsing by Subject "Antiangiogenetic-therapy"
Now showing items 1-1 of 1
-
VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
( BioMed Central , 2018 , Article)Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized ...